Named on 3 rounds in the feed, most often in Biotech.
Rounds from 2025-01-09 to 2025-10-15
ROUNDS
3
led every one
LED ROUNDS · USD
$495.5M
across 3 rounds · 2 co-led, split evenly
CO-INVESTORS
22
most often with Nextech Invest
Named on 3 rounds in the feed, most often in Biotech.
Rounds from 2025-01-09 to 2025-10-15
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Tubulis Tubulis develops antibody-drug conjugates for treating various cancers. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $358.0M | 2025-10-15 | [ LEAD ] |
Airna AIRNA develops RNA editing therapeutics aimed at delivering functional cures for patients with rare diseases and common conditions. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $155M | ~ 2025-04 | [ LEAD ] |
Timberlyne Therapeutics Timberlyne Therapeutics develops biopharmaceutical therapies for autoimmune diseases. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $180M | 2025-01-09 | [ LEAD ] |